Led by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Experimental Therapeutics Group, in collaboration ...

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is incurable. The disease is characterized by the ...

A new study identifies two proteins that interact with a mutant FUS variant linked to familial ALS, offering a potential ...

University of Cologne scientists identified histone H1.2 and PARP1 as potential therapeutic targets in ALS. Inhibiting these proteins reduced neurodegeneration in both human motor neurons and C.

Targeting two proteins, called H1.2 and PARP1, may lessen the severity of amyotrophic lateral sclerosis linked to FUS mutations.

Aug. 22, 2024 — Scientists have found that the protein histone H1.2 and the enzyme PARP1 could be potential therapeutic targets to decrease neurodegeneration in amyotrophic lateral sclerosis ...

Merck gets exclusive rights to Hengrui’s PARP1 drug HRS-1167 outside China under the terms of the agreement, and also picks up an option for an ex-China license to SHR-A1904, an ADC directed at ...

The two proteins which interacted with the mutant FUS protein were PARP1, an enzyme promoting poly ADP-ribosylation (PARylation), a modification that can alter proteins in different ways ...